Many Guidelines, Much Confusion. Blood Pressure Targets in the Elderly

Seeing as hypertension prevalence and incidence increases with age, treating elderly patients of paramount importance.

Las nuevas guías Europeas de Hipertensión contrastan con las Americanas

The AHA/ACC guidelines have lowered cohort hypertension thresholds to >130/80 mmHg, whereas the European guidelines have kept the classic >140/90 mmHg, though recommending lower thresholds for most patients at the same time. Lower than 130/80 mmHg is recommended with the exception of very frail patients and ≥65-year olds.

Anyway, given the J curve between values and events, this is the first time the recommended targets are 120-129 mmHg systolic blood pressure and 70-79 mmHg diastolic blood pressure.

In contrast, the AHA/ACC guidelines have issued recommendations regardless of age, which made other American societies publish guidelines dedicated to patients over 60.


Read also: Loss in Life Expectancy after Surgical Aortic Valve Replacement.


The European Heart Journal will soon publish a prospective analysis carried out by Douros et al. of the Berlin Initiative Study, where a <140/90 mmHg target was associated to an increase in all-cause mortality risk in 1628 patients of mean 81 years old.

In conclusion, <140/90 mmHg blood pressure (BP) values were associated with 26% increased risk in all-cause mortality. This increase was basically driven by patients reaching <130 mmHg systolic BP targets.

Por patients over 70, there was a trend in favor of reduced mortality with <140/90 mmHg values.

Nonetheless, the authors have documented a 40% increased risk in all cause morality for patients over 80 and a 61% increased risk for patients that also had a history of cardiovascular events.


Read also: Vena Cava Filter for All Patients After Severe Trauma.


Interestingly, the risk curve for all-cause mortality associated to systolic BP is U shaped.

Even though the AHA/ACC and ESC/ESH guidelines were published practically at the same time and were based on virtually the same evidence, they show large discrepancies. For example, the cutoff value to start medication in a 64-year old with no prior events and low risk may vary as much as 20 mmHg, depending on which of the guidelines their physician decides to follow.

Even the elderly condition might be difficult to define; a definitive cutoff value can be practical and serve as guideline, but it reflects a partial point of view since, we know, not all of us age the same way.

Data are quite limited when it comes to the elderly (>80 years), a population that, to make matters worse, is on the rise, as are very frail patients requiring home care, or senile patients, who are seldom included in controlled studies.


Read also: Clinical Implications of the New Hypertension Guidelines.


Given the physiopathological conditions of the elderly (limited baroreflex, arterial elasticity, ventricular compliance, and kidney failure) antihypertensives should be indicated with caution, and here is where the medical criterion should set the course, rather than the guidelines.

Original Title: Blood pressure targets in the elderly: many guidelines, much confusion.

Reference: Sebastian Ewen et al. European Heart Journal (2019) 0, 1–3. Article in press.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Ticagrelor vs Clopidogrel in ACS Patients Receiving DOAC After PCI: More Bleeding Without Ischemic Benefit?

In patients with acute coronary syndrome (ACS) who require direct oral anticoagulation (DOAC) and undergo percutaneous coronary intervention (PCI), current guidelines recommend a dual...

EuroPCR 2026 | P2Y12 Inhibitor Monotherapy After Complex PCI in ACS: Results From the NEO-MINDSET COMPLEX Subanalysis

This is a summary of the NEO-MINDSET COMPLEX subanalysis, presented by Dr. Guy Prado at EuroPCR 2026, which evaluated P2Y12 inhibitor monotherapy versus dual...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

Inflammation after TAVI: An Emerging Therapeutic Target?

Conduction disturbances and the need for permanent pacemaker implantation remain common complications following TAVI, with an incidence approaching 15%. Although they have traditionally been...

SPYRAL Program: 3-Year Outcomes in Patients Treated with Renal Denervation

Hypertension is the leading modifiable risk factor for cardiovascular disease and remains a major global health challenge, affecting more than one billion adults worldwide.  Despite...

Coronary Obstruction During TAVI: A New Volumetric Index to Consider

Coronary obstruction during TAVI is an uncommon but potentially catastrophic complication, particularly in valve-in-valve procedures, in anatomies with small sinuses of Valsalva, low coronary...